Philip B. Rawlins
AstraZeneca (Brazil)(BR)
Publications by Year
Research Areas
Phagocytosis and Immune Regulation, Receptor Mechanisms and Signaling, Protein Degradation and Inhibitors, Monoclonal and Polyclonal Antibodies Research, PARP inhibition in cancer therapy
Most-Cited Works
- → Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia(2018)480 cited
- → EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex(2019)194 cited
- → Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain(2016)192 cited
- → Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6(2018)136 cited
- → Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors(2017)78 cited
- → Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)(2019)77 cited
- → Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?(2015)73 cited
- → Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition(2021)62 cited
- → Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors(2016)60 cited
- → A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation(2023)36 cited